TY - JOUR
T1 - Antihuman-TAA-antibodies can isolate p53 antigen from the serum of cancer patients and can be used as a new tool for colon cancer diagnosis
AU - Zusman, I.
AU - Zusman, R.
AU - Korol, D.
AU - Sandler, B.
AU - Smirnoff, P.
AU - Bass, D.
AU - Or, A.
AU - Shani, A.
AU - Adalevich, E.
AU - Huszar, M.
AU - Tendler, Y.
AU - Glick, J.
PY - 1996
Y1 - 1996
N2 - The early cancer detection remains highly problematic, and modern methods do not always show positive results. We developed a new serological method for cancer detection using antibodies generated against the human tumor-associated antigens (TAA). The method is based on the determination of the serum-level of tumor-associated p53 kD cytoplasmic antigen in the cancer and non-cancer patients. The correlation coefficient between this protein and the total serum amount of TAA or total serum protein ranged from 0.55 to 0.93. The serum level of p53 protein was shown to be related to cancer. Therefore, the determination of its serum concentration can serve as a screening tool for cancer detection. The serum level of p53 protein ranges between 0.24 and 0.94 mg/ml in patients with non-cancer diseases, and between 1.0 to 2.0 mg/ml in patients with polyposis and in a high risk group, respectively, increased over 2.0 mg/ml in primary colon cancer patients and up to 5.0 mg/ml in cancer patients with metastases. The sensitivity and specificity of our method are 92% and 96% respectively, and accuracy is 88%. A strong correlation has been found between Duke's stage in colon cancer and the serum level of p53 protein. The presence of p53 protein in the cytoplasm of cells from patients with non-cancer disease may explain why p53 protein is presented in their sera. Our method can be useful to detect cancer development either as a primary illness or as a recurent disorder. It is possible to follow up patients with chronic diseases and to detect transformation of these diseases into cancer, or to follow-up former cancer patients in order to detect as early as possible incidence of recurrent cancer. It should also be emphasized that our method allows the detection of patients with polyposis or those of high risk groups who exhibit a tendency to develop colon cancer.
AB - The early cancer detection remains highly problematic, and modern methods do not always show positive results. We developed a new serological method for cancer detection using antibodies generated against the human tumor-associated antigens (TAA). The method is based on the determination of the serum-level of tumor-associated p53 kD cytoplasmic antigen in the cancer and non-cancer patients. The correlation coefficient between this protein and the total serum amount of TAA or total serum protein ranged from 0.55 to 0.93. The serum level of p53 protein was shown to be related to cancer. Therefore, the determination of its serum concentration can serve as a screening tool for cancer detection. The serum level of p53 protein ranges between 0.24 and 0.94 mg/ml in patients with non-cancer diseases, and between 1.0 to 2.0 mg/ml in patients with polyposis and in a high risk group, respectively, increased over 2.0 mg/ml in primary colon cancer patients and up to 5.0 mg/ml in cancer patients with metastases. The sensitivity and specificity of our method are 92% and 96% respectively, and accuracy is 88%. A strong correlation has been found between Duke's stage in colon cancer and the serum level of p53 protein. The presence of p53 protein in the cytoplasm of cells from patients with non-cancer disease may explain why p53 protein is presented in their sera. Our method can be useful to detect cancer development either as a primary illness or as a recurent disorder. It is possible to follow up patients with chronic diseases and to detect transformation of these diseases into cancer, or to follow-up former cancer patients in order to detect as early as possible incidence of recurrent cancer. It should also be emphasized that our method allows the detection of patients with polyposis or those of high risk groups who exhibit a tendency to develop colon cancer.
UR - http://www.scopus.com/inward/record.url?scp=33747779033&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:33747779033
SN - 0956-960X
VL - 7
SP - XIV
JO - Human Antibodies and Hybridomas
JF - Human Antibodies and Hybridomas
IS - 2
ER -